NCT04102241View on ClinicalTrials.gov

Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

October 12, 2020

Study Completion Date

July 21, 2021

Conditions
Psoriasis
Interventions
DRUG

15mg Hemay005

Hemay005 is a small molecule PDE4 inhibitor.

DRUG

Placebos

Placebos are the same as drugs, but contain no Hemay005.

Trial Locations (1)

310009

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT04102241 - Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter